British American Tobacco Plc CFO Soraya Benchikh to step down

British American Tobacco

British American Tobacco Plc (LON:BATS) has announced that Soraya Benchikh is stepping down from her role as Chief Financial Officer and from the Board of Directors of the Company with effect from 26 August 2025.  Soraya will remain available to support the transition until 31 December 2025.

A recruitment process to identify a permanent successor to the role of Chief Financial Officer is being launched. Javed Iqbal, who is currently Director, Digital and Information, will take on the role of interim Chief Financial Officer. Javed recently acted as the Company’s Interim Finance Director from May 2023 until April 2024.

Tadeu Marroco, British American Tobacco Chief Executive, commented:

“Soraya has made a significant contribution to BAT, having worked in various roles within the Group over many years. On behalf of the Board, I would like to thank Soraya for her contribution, most recently in her role as Chief Financial Officer since rejoining the Group in May 2024. We wish her all the best with her future plans.

As we set out at our recent results, our performance in the first half of the year was slightly ahead of our expectations, and we are firmly on track to deliver our full year guidance. With the right strategy we intend to continue to deliver on the profitable transformation of BAT, reflected in our stated ambitions for 2026 and beyond.  We will update on our continued progress in our pre-close trading update in December.”

Soraya Benchikh commented:

“I am proud of my role in the significant progress since I joined BAT, as reflected in our recent results.

Further embedding financial discipline and putting New Categories on a path to accretive margins and sustainable profitability have been key contributions to that progress. This was made possible thanks to the incredibly talented and dedicated teams I have had the privilege to work with across BAT. Now is the right time for me to move on to my next transformation. I wish the BAT team every success in taking the business to the next level.”

Supplementary Information – Remuneration

All remuneration arrangements are consistent with the terms of the Directors’ Remuneration Policy approved by shareholders at the AGM in April 2025. 

In accordance with section 430(2B) of the Companies Act 2006, information in respect of Soraya Benchikh’s departure from the Board will be available on bat.com in due course and will remain available until the Company’s Directors’ Remuneration Report in the Annual Report for the year ended 31 December 2025 is made available.

Share on:
Find more news, interviews, share price & company profile here for:

    HUTCHMED CEO Dr Weiguo Su takes leave of absence

    HUTCHMED (China) has announced that Chief Executive Officer Dr Weiguo Su will take a leave of absence due to health reasons. The Board has appointed Johnny Cheng, the company’s Chief Financial Officer and Executive Director, as Acting CEO while continuing in his CFO role.

    Filtronic secures £47.3m SpaceX contract for next-generation GaN technology

    Filtronic has signed its largest single order to date, a £47.3m ($62.5m) contract with SpaceX for its next generation gallium nitride (GaN) E-band product. The first units will ship in FY2027, with revenues expected in FY2027 and FY2028, marking a major milestone in the company’s partnership with SpaceX and its development of advanced RF solutions.

    EDX Medical reports 2025 results and advances in cancer diagnostics

    EDX Medical Group has published its Annual Report for the year ending 31 March 2025, highlighting the development of a new AI-driven prostate cancer test, a £3 million fundraising, expanded European partnerships, and a service agreement with Royal Marsden NHS Foundation Trust.

    Diverse Income Trust reports £257.9m net assets with 4.18% yield

    Diverse Income Trust reported net assets of £257.9 million as of 31 July 2025, with a NAV of 109.08p per share and a share price of 104.00p, reflecting a 4.66% discount. The trust, managed by Gervais Williams and Martin Turner, delivered a 19.42% one-year share price total return and maintains a historic yield of 4.18%.

    Aptamer advances enzyme modulation projects and expands pharma collaboration

    Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors.

    Structured products fund Volta Finance reports July NAV of €274.2m, performance up 2.5%

    Volta Finance has reported a July net performance of +2.48%, including a dividend of 15.5 cents per share, bringing financial year gains to +13.9%. Net Asset Value stood at €274.2m (€7.49 per share), with strong contributions from CLO equity tranches, which returned +5.2% during the month

      Search

      Search